CBG in Focus

CBG Discovery

Cannabigerol (CBG), ‘the mother of all cannabinoids’, is a rare non-psychoactive cannabinoid. It was first isolated in 1964 by Raphael Mechoulam, the father of cannabinoids, and his colleagues Yechiel Gaoni and Yuval Shvo from the Weizmann Institute in Rehovot (Israel); one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. Since then researchers mostly focused on the Cannabidiol (CBD) and Tetrahydrocannabinol (THC), so most research on CBG happened in the past decade.

CBG Research

While the research on CBG is relatively limited, findings of recent preclinical studies show that CBG has great potential in treating numerous health issues and in providing beneficial health effects.

CBG triggers receptors that specifically affect mood supporting normal stress response, pain management, and appetite. It showed anti-nausea effect providing nausea and vomiting relief.

CBG has also shown potential in the treatment of neuroinflammation, Parkinson’s disease (Study 1, Study 2), Huntington’s disease (Study 1, Study 2) and Multiple Sclerosis. A 2013 study confirmed CBG’s potentially positive effect on IBS patients. Furthermore, there is evidence that CBG fights gram-positive bacteria associated with tooth caries and MRSA, the drug-resistant bacteria that causes staph infections.

When it comes to cancer treatment, CBG has demonstrated potential in epithelioid carcinoma and was second in potency to CBD in breast cancer cell lines. There are also suggestions of possible benefits in the treatment of prostate cancer, colon cancer, bladder pain and bladder dysfunction. Further research has shown that CBG reduced the viability of glioblastoma tumors and stem cells comparable to THC, and its combination with CBD was more effective than THC in the induction of caspase-dependent programmed cell death.

Cannabigerol was also found to mildly lower blood pressure and intraocular pressure, suggesting a therapeutic use in the treatment of glaucoma. Its ability to reduce the proliferation of keratinocytes also suggests a potential in treating psoriasis.

CBG – Quality matters

Led by science and guided by our team of leading physicians, Verséa Hemp-Derived CBG Oral Sprays bring patented extraction process and fast-absorption technology that speeds up-take and delivers maximum benefits.

4.4x greater and 3x faster absorption guaranteed!

The easy-to-use metered pump dosing simplifies the use and allows precise dosing of the active ingredient whole avoiding mess. You are always in control of your intake. Each pump provides 4.5 mg of CBG that can mix easily with fluids or be administered directly in mouth

To purchase high quality, clinically tested CBG products, visit our SHOP. To acquire more information about how CBG can be beneficial to you, contact Verséa Wellness specialists at +1 (800) 397-0670 or info@getversea.com.